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TuberculosisAbstract Background: Non-responding pneumonia is usually a topic of interest for pulmonolo-
gists. Fiberoptic bronchoscopy (FOB) and bronchoalveolar lavage (BAL) may be an important tool
in assessment of non-responding pneumonia. There is paucity of recent studies in this area.
Aim: This study aimed to assess the impact of early bronchoscopy and BAL in etiological diag-
nosis of the patients with non-responding pneumonia with special emphasis on efﬁcacy of FOB and
BAL in diagnosis.
Settings and design: A prospective, observational study was conducted in chest and medical
microbiology and immunology departments, Zagazig University Hospitals.
Patients and methods: There were total 135 patients included in our study after fulﬁlling the cri-
teria of non-responding pneumonia by clinical and laboratory parameters, patients were subjected
to FOB and BALF microbiological, cytological, histopathological investigations.
Results: The patients were 90 males and 45 females with a mean age of 47.6 ± 12.2 years. Uni-
lateral lung involvement was seen in 108 (80%) patients, whereas bilateral involvement in 27 (20%)
patients. Right upper lobe was the most commonly involved site (25.9%). In this study, bacterial
pneumonia 83.71% was found to be the commonest etiology of non-resolving pneumonia, followed
by bronchogenic carcinoma 13.3% and tuberculosis 2.96%. FOB was done for all patients. BAL
ﬂuid results were 88 positive, gram stain samples (65.1%), 4 BAL ZN stain and mycobacterial cul-
ture positive cases (2.96%), pyogenic organisms were isolated in 113 patients 83.71% by BAL ﬂuid
culture. Bronchoscopic biopsies were also performed in 18 cases. BAL ﬂuid cytology was positive in
6 cases (33.3%), transbronchial forceps biopsy positive results were found in 10 cases (55.55%) and
bronchial brushing showed positive results in 3 cases (16.66%).
Conclusions: NRP is common and represents a difﬁcult clinical problem as the cause may vary
from a benign delay in recovery to life-threatening progressive pneumonia. A systematic approach17613.
614 M. El-Shabrawy, R.H. EL-Sokkaryto investigation and management is recommended with consideration of both infectious and non-
infectious causes.
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One of the most common acute medical conditions requiring
hospitalization is community-acquired pneumonia (CAP).
Most of hospitalized patients with CAP respond rapidly to
antibiotic therapy and follow an uncomplicated course, but a
proportion of patients fail to respond to initial therapy and
require additional investigations and treatment [1,2]. Despite
great advance in clinical care, the mortality rate remains 5–
15%. Patients with non-responding or progressive pneumonia
represent a group of patients where appropriate early interven-
tion can improve outcome while preventing overtreatment [3,4].
Radiological evaluation of response to treatment has tradi-
tionally been difﬁcult to deﬁne because changes, can take up to
6 weeks to resolve and often lag behind the clinical recovery of
patients. However microbiological results becomes negative
very quickly after initiation of empirical antibiotic treatment
as, inﬂammatory process then begins to resolve, by a reduction
in inﬂammatory cytokines and biomarkers such as C-reactive
protein (CRP) [5]. Also, patient symptoms start to improve,
as the systemic inﬂammation resolves, until they reach the state
of ‘clinical stability’. At this stage, pneumonia is considered to
have responded to treatment, and prognosis at this point is
excellent, complications are rare, and relapse is unusual [6].
The non-responding pneumonia frequency is difﬁcult to
estimate due to lack of a uniform deﬁnition to it. If we agree
that NRP to be deﬁned as a failure to achieve clinical stability
by day 3, so, the frequency of ‘non-responding’ pneumonia
will reach as high as 40% [7].
A number of studies recorded that ﬁberoptic bronchoscopy
with bronchoalveolar lavage, brush biopsy and transbronchial
biopsy can successfully reach about 90% of etiological diagno-
sis in NRP patients who eventually have a speciﬁc diagnosis
[8]. The aim of the present study was to assess the impact of
early bronchoscopy and BAL in etiological diagnosis of the
patients of non-responding pneumonia with special emphasis
on efﬁcacy of FOB and BAL in diagnosis.
Patients and methods
This prospective, observational study was conducted in chest
and medical microbiology and immunology departments,
Zagazig University Hospitals, in the period from September
2013 to February 2015. The study was carried out on 135
patients with community acquired pneumonia not responding
to treatment (90 males and 45 females), their ages ranged from
18 to 60 years with a mean of 47.6 ± 12.2 years, who were
admitted to Chest Department.
Patients
The patients were enrolled to this study according to the fol-
lowing criteria.Inclusion criteria
Patients who were 18 years or older with clinical and radio-
graphic evidence of CAP. Pneumonia diagnosed by clinical
signs and symptoms: cough with or without sputum, fever
>38.5 C, dyspnea, pleuritic chest pain or abnormal breath
sounds and radiographic pulmonary abnormalities that are
at least segmental and are not due to preexisting or other
known causes which was acquired at the community or within
the ﬁrst 48 h of hospitalization [9]. Patients who were not
responding after 3 days of hospital admission, identiﬁed by
persisting fever and/or clinical symptoms (malaise, cough,
expectoration, dyspnea) after empirical antimicrobial treat-
ment [10].
The deﬁnition of non-responding pneumonia ‘NRP’ is not
clearly established. Treatment failure pneumonia is deﬁned
as delayed radiographic improvement or deterioration
according to worsening of radiology, which have proven to
be relatively insensitive markers of treatment response so,
non-responding pneumonia is therefore better accepted as a
lack of an adequate clinical response to treatment, and there-
fore, a failure to reach clinical stability in the expected period
of time [11,12]. The duration to achieve the clinical stability in
most studies is 3 days; for this reason, routine re-evaluation of
all hospitalized patients still at day 3 to identify patients with
NRP is done [13].
Exclusion criteria
Patients were excluded if any of the following was met:
Nosocomial pneumonia or healthcare-associated pneumo-
nia (HCAP), severe immunosuppression (HIV, use of
immunosuppressant such as cytotoxic drugs, cyclosporins or
monoclonal antibodies) and admission in an intensive care
unit.
All the patients received antibiotic therapy on admission
according to Infectious Diseases Society of America/American
Thoracic Society (IDSA/ATS) 2007 guidelines [14]. The
following antibiotic regimens were given: empirical
antibiotic regimen (according to drug availability at time of
admission).
Levoﬂoxacin 500 mg/24 h I.V., cefotaxime 1 g/12 h I.V. and
azithromycin 500 mg/24 h I.V., ampicillin–sulbactam 1.5 g/8 h
I.V. combined with azithromycin 500 mg/24 h I.V. and ceftri-
axone 1 g/24 h I.V. and azithromycin 500 mg/24 h I.V.
Methods
Included patients were subjected to the followings:
(1) Thorough medical history: history taking from the
patients. Smoking history and history of other comorbid dis-
eases etc.
(2) Full clinical examination: including both general and
local chest examinations. Evaluations of improvement were
done by comparison between vital signs on day 1 and day 4.
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measure the severity of CAP for patients. Twenty-four hours
after hospital admission, the scoring has been completed and
resulted in an integrated point score between 0 and >130.
According to PSI scoring patients were classiﬁed into:
a. Class I: Points 0: Mortality 0.1% (low risk)?Mild.
b. Class II: Points <70: Mortality 0.6% (low risk)?Mild.
c. Class III: Points 71–90: Mortality 2.8% (low risk)?
Mild.
d. Class IV: Points 91–130: Mortality 8.2% (moderate
risk)?Moderate.
e. Class V: Points >130: Mortality 29.2% (high risk)?
Severe [9].
(4) Laboratory investigations: were done at day 1 and day 4.
(a) Complete blood count.
(b) Kidney function tests (serum urea level and creatinine).
(c) Liver function tests.
(d) Serum electrolytes (Na and K).
(e) Arterial blood gas analysis.
(f) Serum level of C-reactive protein (CRP).
Fresh blood sample was drawn from peripheral vein when
CAP was diagnosed. CRP was measured by ELISA assay
using a commercially available kit (Tina-quant CRP; Roche
Diagnostics, Mannheim, Germany). For this assay, the lower
limit of detection was 1.38 mg/L, and the standard curve
ranges between 5 mg/L and 170 mg/L. and the normal value
for CRP was up to 6 mg/L [15].
(5) Radiological investigation:
a. Plain chest X-ray: posteroanterior view was done to all
patients at day (1) and (4) by X-ray machine (ROTALiX
SRT 32, Philips, Italy).
b. Computed tomography (C.T.): conventional chest C.T.
was done for all cases to conﬁrm diagnosis of pneumo-
nia detects any complication. It was done by chest C.
T. (Hi-speed spiral C.T., GE Medical Microsystem,
Xi’an 710075, China).
(6) Microbiological investigation: blood culture and sputum
examination by gram stain and culture were done for all
patients [16].
(7) Bronchoscopy: All patients were subjected to FOB
(Pentax FB15TV, Philips, Tokyo, Japan), as they were not
responding to empirical antibiotic therapy. Flexible bron-
choscopy was performed with ﬁberoptic scope through trans-
nasal route under topical anesthesia (2% lignocaine).
Oxygenation was monitored throughout the procedure with
pulse oximetry [17].
Appropriate samples such as BAL for all patients, brush-
ing for 7 patients and biopsy for 10 patients were obtained
depending on the lesion after thorough evaluation of endo-
bronchial tree during the procedure. Samples were subjected
to cytology, histopathology, AFB staining and culture/
sensitivity, depending upon the clinical diagnosis and
bronchoscopic ﬁndings.Procedure of BAL
Specimen collection
Under complete aseptic conditions the following was done
with continuous monitoring of the pulse, blood pressure, and
oxygen saturation throughout the whole procedure. The scope
then was wedged into the oriﬁce of the bronchus draining the
segment likely to be involved, as judged radiologically, or, in
cases of diffuse radiologic presentation, in the posterior
bronchus of the lower lobe. As little topical lidocaine as possi-
ble was used so as not to interfere with bacterial growth
(never > 20 mg per bronchus). Aspiration of secretions by
the bronchoscope was avoided. The sample was collected after
instilling three aliquots of 50 mL sterile saline (0.9% NaCl
solution) through the bronchoscope. At least 40% of injected
saline was suctioned. The bronchoscope was then removed
from the patient’s airway.
The sample was sent immediately for culture. The presence
of >1% squamous epithelial cells suggested a highly contam-
inated specimen [18].
Microbiological processing
BAL samples were mechanically liqueﬁed and homogenized by
vortexing for 1 min with glass beads, followed by centrifuging
at 3000 rotations per minute for 10 min [19]. After obtaining
our microbiological samples, an empirical change in antibiotic
therapy with combinations that cover broad microbial etiolo-
gies is mandatory for those non responding patients.
Antibiotic susceptibility test
The susceptibilities of the collected isolates were determined by
the Kirby–Bauer disk diffusion method using Mueller Hinton
agar plates as recommended by the Clinical and Laboratory
Standards Institute (CLSI) [20].
Freshly isolated colonies were suspended in isotonic saline
to match the turbidity of 0.5 McFarland standard suspensions.
They were streaked using sterile swabs over the surface of
Mueller Hinton agar plates. Disks loaded with different tested
antimicrobial agents were transferred to the surface of the
inoculated plates and gently pressed. The antimicrobial disks
were obtained from Oxoid, UK and Bioanalyse, Turkey.
The tested antimicrobials were: amikacin (30 lg), ampicillin
sulbactam (SAM) (20 lg), co-amoxiclav (amoxicillin/
clavulanic acid 20/10 lg), piperacillin–tazobactam 100/10 lg,
etrapenem (10 lg), meropenem (10 lg), cefotaxime (30 lg),
cefepime (30 lg), cefoperazone (75 lg), cefuroxime (30 lg),
ceftriaxone (30 lg), ceftazidim (30 lg), azithromycin
(15 lg), clindamycin (2 lg), ciproﬂoxacin (5 lg), levoﬂoxacin
(5 lg), co-trimoxazole (trimethoprim/ sulfamethoxazole
1.25/23.75 lg), moxiﬂoxacin (5 lg) and vancomycin (30 lg ).
The plates were incubated at 37 C for 16–18 h. The inhibition
zone diameters were measured to the nearest millimeter and
recorded. Isolates that were resistant to three or more classes
of antimicrobials were considered as multi drug resistant
isolates [21].
(8): hospital outcome was then evaluated and tabulated
patients were classiﬁed according to hospital outcome.
(9) Statistical analysis: all data were collected, tabulated
and reformed for statistical analysis using Statistical Package
Table 1 Patient characteristics (n= 135).
N= 135
ITEM Mean ± SD
Age (years) 47.6 ± 12.2
N %
Sex
Female 45 33.3
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The results of this work were analyzed and presented as num-
bers and percentage or mean ± standard deviation (SD). Stu-
dent’s ‘‘t” test, analysis of variance (ANOVA) and Chi-square
(v2 test or Fisher’s exact test) were used for comparisons
between group’s data. A P-value < 0.05 was considered
signiﬁcant and P-value < 0.001 was considered highly
signiﬁcant [22].Male 66.7 90
Smoking Smoker 87 64.4
Goza 31 35.63
Cig. 40 45.98
Combined 16 18.39
Non smoker 48 35.6
Pneumonia severity index (PSI)
I 12 8.9
II 48 35.6
III 40 29.6
IV 35 25.9
V 0 0
Comorbidities 54 40
Diabetes mellitus 16 29.62
Hypertension 14 25.92
Ischemic heart disease 10 18.55
Liver diseases 5 9.25
COPD 9 16.66
Table 2 Clinical and laboratory data of patients who fail to
improve.
Day At day 1 At day 4 P
Data
Fever 38.54 ± 0.62 38.56 ± 0.56 0.07
Heart rate 119.2 ± 11.9 119.02 ± 11.4 0.07
Respiratory rate 22.02 ± 3.6 22 ± 3.41 0.80
Systolic bl. Pr. 104.22 ± 23.5 103.96 ± 11.6 0.06
Diastolic bl. Pr. 73.7 ± 7.6 73.6 ± 8.2 0.06
CRP level 17.32 ± 3.52 17.15 ± 3.15 0.14
WBCs count 99.51 ± 38.3 98.79 ± 33.9 0.06Results
During the period from September 2013 to February 2015, 135
patients of both sexes, diagnosed as non-responding pneumo-
nia according to our study criteria, were included in this study.
Overall, mean age of the patients was 47.6 ± 12.2 years, 45
patients (33.3%) were females and 90 (66.7%) males. Fifty-
four patients (40%) had at least one comorbidity, diabetes
mellitus was by far the most common (29.62%) followed by
hypertension (25.92%), ischemic heart diseases (18.55%), liver
diseases (9.25%), and chronic obstructive pulmonary diseases
(16.66%). Eighty-seven patients (64.4%) were smokers and
48 (35.6%) were non-smokers (Table 1).
After four days of hospitalization, non-responding patients
remained febrile, continued to experience raised WBCs and
CRP levels. Respiratory rate, heart rate and blood pressure
had no change. These abnormalities coexisted in some patients
(Table 2).
As regards radiological ﬁndings in the studied patients,
unilateral lung involvement was seen in 108 (80%) patients,
whereas bilateral involvement in 27 (20%) patients. Right
upper lobe (25.9%) was the most common involved site, fol-
lowed by right lower lobe (21.5%), left lower lobe (17.78%),
and left upper lobe (14.8%). Bilateral involvement was seen
in 27 (20%). On chest X-ray, consolidation was present in
113 patients (83.7%), consolidation along with cavity was pre-
sent in 13 patients (9.6%) and consolidation along with effu-
sion was present in 9 (6.7%) patients. On the other hand, by
CT scan of the thorax other ﬁndings were recorded, such as,
mediastinal lymphadenopathy in 11 (8.14%) patients, collapse
in 8 (5.9%) patients and increased cases of effusion to be 17
(Table 3).
Our ﬁndings in this study for causes of non-responding
patients were pyogenic infection in 113 (83.71%) followed by
malignancy in 18 (13.33%) and 4 tuberculous in patients
(2.96%) (Table 4).
The yield of different diagnostic techniques either broncho-
scopic or non bronchoscopic specimens ranging from 0% to
83.7% with sputum Zn having the lowest yield and BAL ﬂuid
culture and sensitivity having the highest one. Fiberoptic bron-
choscopy was done for all patients. BAL ﬂuid results were; 88
positive for gram stain samples (65.1%), 4 BAL Zn stain and
mycobacterial culture positive cases (2.96%), pyogenic organ-
isms were isolated in 113 patients (83.7%) by BAL ﬂuid cul-
ture. Bronchoscopic biopsies were also performed in 18 cases
according to bronchoscopic ﬁndings. BAL ﬂuid cytology was
positive in 6 cases (33.3%), transbronchial forceps biopsy pos-
itive results were 10 cases (55.5%), and bronchial brushing
showed positive results in 3 cases (16.66%) (Table 5).
The spectrum of bacterial isolates obtained from the BAL
ﬂuid analysis was 113 pyogenic and 4 mycobacterial isolates.
Klebsiella pneumoniae was the most common isolate obtained,29 isolates (24.78%), followed by both Pseudomonas aerugi-
nosa and Streptococcus pneumonia 23 isolates (Table 6).
Discussion
Non-responding pneumonia is not an infrequent clinical prob-
lem that faces pulmonologists. The terms NRP and treatment
failure are often used interchangeably, but in fact, both are
quite different entities. It is very important to deﬁne treatment
response and non-response for proper clinical decision-
making, such as, switching medication from intravenous to
oral with stepping down, hospital discharge and also, taking
into account non-infective causes for that pulmonary inﬁltrate
which called ‘pneumonia mimics [23].
Chalmers et al. [24] reported that, non-responding pneu-
monic patients, who don’t reach clinical improvement at day
3, should be re-evaluated. Reevaluation of physical examina-
tion alongside some important investigations such as CRP
Table 6 Bacterial spectrum of BAL ﬂuid analysis.
Organism Number Percentage
Monomicrobial 109 93.2
Klebsiella pneumoniae 29 24.79
Streptococcus pneumoniae 23 19.66
Pseudomonas aeruginosa 23 19.66
Staphylococcus aureus 18 15.53
Escherichia Coli 16 13.56
Polymicrobial. 4 3.4
Mycobacterial tuberculosis 4 3.4
Total 117 100
Table 3 Radiological ﬁndings in all studied patients.
Frequency Percent
CXR Bilaterality Unilateral 108 80
Bilateral 27 20
Distribution Rt. upper lobe 35 25.9
Right lower
lobe
29 21.5
Left lower lobe 24 17.78
Left upper lobe 20 14.8
Bilateral 27 20
Findings Consolidation 113 83.7
Consolidation
and eﬀusion
9 6.7
Consolidation
and cavitation
13 9.6
CT Cavity 14 10.4
Consolidation 135 100
Eﬀusion 17 12.6
Mediastinal
lymphadenopathy
11 8.14
Collapse 8 5.9
Table 5 Yield of different laboratory measurements and
bronchoscopic procedures.
Parameter Positive/n (%)
Sputum analysis n= 135
Sputum gram stain positivity 85/135 (62.9)
Sputum Zn stain positivity 0/135 (0)
Sputum C/S positivity 5/135 (3.7)
Blood analysis n= 135
Blood culture positivity 9/135
Pleural ﬂuid analysis n= 17
Pleural ﬂuid gram stain positive cases 4/17 (23.52)
Pleural ﬂuid C/S positivity 2/17 (11.76)
BAL analysis n= 135
BAL gram stain 88/135 (65.1)
BAL ZN 4/135 (3)
BAL mycobacterial culture 4/135 (3)
BAL C/S 113/135 (83.7)
Cytology and histopathology n= 18
BAL cytology 6/18 (33.3)
Transbronchial forceps biopsy 10/18 (55.55)
Brush biopsy 3/18 (16.66)
Table 4 Etiology of non-responding pneumonia diagnosed by
bronchoscopy.
Diagnosis No. of cases N= 135 (%)
Bacterial pneumonia 113 (83.71)
Malignancy 18 (13.33)
Tuberculosis 4 (2.96)
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cal and blood sampling investigations to be informative, bron-
choscopy is most likely to be a good diagnostic tool where
multidrug resistant microbes or endobronchial lung cancer
may be present. Use of bronchoscopy and bronchoalveolar
lavage is recommended in such patients [23].BAL provides a very useful tool for diagnosing lower respi-
ratory tract infection and can be performed safely and rapidly.
Although conventional BAL performed without the use of
protected catheters may be contaminated, there is no evidence
that protected BAL provides more reliable results than con-
ventional BAL [25].
So, the aim of this study was to evaluate the important role
of early bronchoscopy and BALF in etiological diagnosis of
the patients of non-responding pneumonia with special empha-
sis on efﬁcacy of FOB and BAL in diagnosis.
This study was conducted on 135 patients diagnosed as
non-responding pneumonia (90 males and 45 females), with
a mean age of 47.6 ± 12.2 years. All patients had pneumonia
severity index less than class v (Table 1) This was in agreement
with Schroder et al. [26] and Angele et al. [27] who observed
the differences between men and women in their studies and
suggested that females are less likely to develop complications
and this sex differences may be due to both the biological
response to infection and patterns of health care delivery.
Regarding smoking, 87 patients (64.4%) were smokers and
48 (35.6%) was non-smokers. Smoking is a well-known risk
factor for CAP through alterations of the host defense mecha-
nisms. There is consistent evidence in many studies that shows
association between smoking habits and CAP development as
reported by Pedro-Botet et al. [28] and Straus et al. [29].
Fifty-four patients (40%) had at least one comorbidity, dia-
betes mellitus was by far the most common (29.62%) followed
by hypertension (25.92%), ischemic heart diseases (18.55%),
liver diseases (9.25%), and chronic obstructive pulmonary dis-
eases (16.66%) (Table 1). Similar comorbidities were recorded
by Confalonieri et al. [30], who found those comorbidities but
did not report an impact of each one on their studied groups,
while Meijvis et al. [31] reported other comorbidities with dif-
ferent frequencies: congestive heart failure (16%), diabetes
mellitus (15%), renal disease (13%), chronic obstructive
pulmonary diseases (13%), neoplastic disease (6%) and liver
disease (1%).
As regards clinical and laboratory parameters at days 1 and
4 the studied patients had no changes (Table 2). Near similar
results were reported by Finch and Chalmers [32] who classi-
ﬁed their patients by day 4, as responding and non-
responding. Non-responding patients were identiﬁed if they
met at least one of the following conditions: temperatureP
37.2 C, heart rateP 100 beats/min, respiratory rateP
24 breaths/min, systolic blood pressure 6 90 mmHg, and
oxygen saturation 6 90% or arterial oxygen partial pres-
sure 6 60 mmHg. They also found that, after 72 h of treatment
(day 4), CRP levels between days 1 and 4 showed no changes.
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anterior (PA) and lateral chest radiographs which are valuable
in patients with the possibility of pneumonia, the radiograph
can be useful in differentiating pneumonia from other condi-
tions that may mimic it and also, identify coexisting condi-
tions. Radiography is also useful for evaluating severity of
illness by identifying multilobar involvement and bilaterality
[33].
Fiberoptic bronchoscopy (FOB) was done to 135 patients
where etiological diagnosis is established by different ways.
The yield of different bronchoscopic procedures in our study
was as follows; BAL culture and sensitivity results ‘‘which were
done to all patients” was 83.7%, BAL cytology was 33.3%,
transbronchial forceps biopsy was 55.5% and brush biopsy
was 16.6% (Table 5).
This is in accordance with Silver et al. [34] who investigated
non resolving pneumonic patients by FOB and infections were
the most common etiology obtained in 86% cases.
Although Jimnez et al. [35] performed bronchoscopy to
community acquired pneumonia patients who were receiving
antibiotics; they were able to establish an infective etiological
diagnosis in 81 percent of cases by BAL culture.
Kottmann et al. [36] reported overall yield of 63.4% of
BAL, which was performed within 3 days of starting antimi-
crobials to pneumonia patients.
Hohenadel et al. [37] reported that, the diagnostic
yield of BAL in the diagnosis of pneumonia had been reported
to be 81% (9) in patients with or without immunosuppression.
In a study by Chaudhuri et al. [38] bronchogenic carcinoma
was found to be 26.6%, of which squamous cell carcinoma was
the commonest variety followed by adenocarcinoma. They
reported malignancy as a speciﬁc cause for non-resolving
pneumonia in 11.4% cases in their series and their results were
near our results.
In this study, pyogenic infection was diagnosed as etiolog-
ical agents in 113 (83.71%) cases among them Klebsiella rep-
resenting 24.78%, S. pneumonia 19.65% and Pseudomonas
19.65% were the common pathogens (Table 6). These results
were consistent with considerations of Finch and Chalmers
[32] who reported that non-responding pneumonia was mostly
due to organisms not covered by initial empirical antibiotic
therapy, such as multidrug resistant pathogens, atypical patho-
gens or tuberculosis, or severe infections with a recognized
longer response time to treatment, e.g. Staphylococcus aureus
pneumonia.
In our study, bronchogenic carcinoma was found in 18
patients (13.3%) (Table 4), this was in agreement with Finch
and Chalmers [32] who reported that non-infectious causes
are less frequent than infectious one affecting about 20% of
NRP patients.
Also, Arancibia et al. [10] who studied 444 hospitalized
CAP patients with; 30 patients had NRP. Infection being the
most frequent cause was identiﬁed in 65% of patients, and
non-infectious disorders were present in 35% of patients
(malignancy, cardiac complications and foreign body).
In our study, K. pneumonia was the most common isolate
obtained, 29 isolates (24.78%), followed by both P. aeruginosa
and S. pneumonia 23 isolates (19.65%), 18 (15.53%) S. aureus
isolates, E. coli was 16 (13.56%), 4 polymicrobial infection iso-
lates (3.4%) and Mycobacterial tuberculosis isolates (3.4%)
(Table 6).Near similar results were reported by, Lin et al. [39] who
concluded that K. pneumonia has been implicated in 15%,
32%, and 34% of community-acquired pneumoniae in
Singapore, Africa and Taiwan, respectively. Also, in study
by Motayo et al. [40], who found that in respiratory tract infec-
tions, K. pneumonia was the most prevalent organism with
40.5%, followed by S. pneumonia (21.6%), and the least preva-
lent was poly infection 2.7%.
Other Spain study illustrated that, among the most com-
mon bacterium cultured from the CAP patients who don’t
respond to treatment, P. aeruginosa and S. pneumoniae were
the most common isolates, and both had the same frequency
of occurrence [10].
On the other hand with review of various studies, which
studied hospitalized CAP patients, they reported that 82% of
the patients had bacterial infection and that S. pneumonia
was the most common pathogen isolated, followed by Hae-
mophilus influenzae [41]. In another study involving 70 patients
of CAP, it was concluded that, the most common isolate was
S. pneumoniae (35.8%), followed by K. pneumoniae (22%)
and S. aureus (17%) [42]. Investigators from a tertiary care
center in New Delhi studied 124 cases of CAP at the Internal
Medicine and Pediatric Department and found that the bacte-
rial pathogens in CAP were S. pneumoniae (35.3%), S. aureus
(23.5%), K. pneumoniae (20.5%) and H. influenzae (8.8%) [43]
Our results are not consistent with the above studies, and this
may be explained by the fact that in those studies, routine cases
of CAP were included and not the special subtype of CAP
patients who are non-responding ones. Hence, the spectrum
and distribution of bacterial pathogens may not be similar to
CAP patients who show favorable response.
Silver et al. [34] found that 5.7% of BAL ﬂuid culture of
non-resolving pneumonia was tuberculous and this is near
our results (2.96%) (Table 5).
Conclusion
A systematic approach to investigation and management of
NRP is recommended with consideration of both infectious
and non-infectious causes. Early bronchoscopy and BALF
analysis can play an important role in the evaluation NRP
patients andmay provide or strongly support speciﬁc diagnoses.
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